Company Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
| Country | United States |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Spiro George Rombotis |
Contact Details
Address: 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922 United States | |
| Phone | 908-517-7330 |
| Website | cyclacel.com |
Stock Details
| Ticker Symbol | CYCC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130166 |
| CUSIP Number | 23254L603 |
| ISIN Number | US23254L8019 |
| Employer ID | 91-1766850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Spiro George Rombotis | President, Chief Executive Officer and Executive Director |
| Paul McBarron | Executive Vice President of Finance, Chief Financial Officer, Chief Operating Officer, Secretary and Executive Director |
| Gill Christie | Director of Human Resources |
| Dr. Brian Schwartz M.D. | Interim Chief Medical Officer and Director |
| Grace Kim | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | 8-K | Current Report |
| May 17, 2024 | D | Notice of Exempt Offering of Securities |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 13, 2024 | EFFECT | Notice of Effectiveness |
| May 13, 2024 | 424B3 | Prospectus |
| May 10, 2024 | UPLOAD | Filing |
| May 8, 2024 | ARS | Filing |
| May 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 8, 2024 | DEF 14A | Other definitive proxy statements |